NASDAQ$TYRA
Tyra Biosciences Inc · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
Tyra Biosciences Inc reported its financial results for the second quarter ended June 30, 2026.
The company reported a net loss of $45.6 million for the quarter, driven by increased research and development expenses of $39.2 million. Cash, cash equivalents and marketable securities totaled $353.9 million at quarter end, providing runway into the second half of 2028.
- Net loss increased to $45.6 million from $28.1 million in the prior year quarter due to higher R&D spend.
- R&D expenses rose 61% year-over-year to $39.2 million, primarily from clinical advancement of dabogratinib programs.
- Completed at-the-market offering raising $147.9 million in net proceeds during the first half of 2026.
- Ended the quarter with $353.9 million in cash and marketable securities.
Headline financials
Revenue & EPS history
Tyra Biosciences · Revenue · Quarterly
$0
Forward guidance
Cash runway into second half of 2028; multiple clinical data readouts expected in 2026 and 2027.
Tailwinds
- Strong balance sheet following ATM raise
- Advancing three Phase 2 trials for dabogratinib
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+2.0%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+29.8%
Q3 2021
Best reaction
-11.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2025 | +1.5% | +7.7% | +21.8% | |
| Q3 2025 | +0.3% | +8.4% | +50.6% | |
| Q2 2025 | +0.4% | -4.3% | +17.0% | |
| Q1 2025 | -3.1% | -4.0% | +2.3% | |
| Q4 2024 | -0.8% | -10.5% | +3.9% | |
| Q3 2024 | -5.9% | -6.9% | -8.1% | |
| Q1 2024 | -3.8% | +3.1% | +9.7% | |
| Q4 2023 | +7.0% | +3.0% | -9.7% | |
| Q3 2023 | -6.3% | -8.1% | +2.5% | |
| Q2 2023 | +0.9% | +1.6% | -3.4% | |
| Q1 2023 | -3.3% | +7.0% | +13.1% | |
| Q4 2022 | -3.3% | +0.0% | -9.8% | |
| Q3 2022 | -7.1% | +12.9% | -3.1% | |
| Q2 2022 | +11.1% | +14.7% | -24.0% | |
| Q1 2022 | +0.1% | -5.9% | -17.8% | |
| Q4 2021 | -11.5% | -5.3% | -6.4% | |
| Q2 2021 | +29.8% | +20.3% | -26.6% | |
| Q3 2021 | +29.8% | +20.3% | -26.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro